Global Community-acquired Bacterial Pneumonia Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Description

According to our (Global Info Research) latest study, the global Community-acquired Bacterial Pneumonia market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Community-acquired Bacterial Pneumonia industry chain, the market status of Hospital Pharmacies (Pleuromutilin Antibiotic, Cephalosporin), Retail Pharmacies (Pleuromutilin Antibiotic, Cephalosporin), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Community-acquired Bacterial Pneumonia.

Regionally, the report analyzes the Community-acquired Bacterial Pneumonia markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Community-acquired Bacterial Pneumonia market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Community-acquired Bacterial Pneumonia market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Community-acquired Bacterial Pneumonia industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Pleuromutilin Antibiotic, Cephalosporin).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Community-acquired Bacterial Pneumonia market.

Regional Analysis: The report involves examining the Community-acquired Bacterial Pneumonia market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Community-acquired Bacterial Pneumonia market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Community-acquired Bacterial Pneumonia:
Company Analysis: Report covers individual Community-acquired Bacterial Pneumonia players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Community-acquired Bacterial Pneumonia This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital Pharmacies, Retail Pharmacies).

Technology Analysis: Report covers specific technologies relevant to Community-acquired Bacterial Pneumonia. It assesses the current state, advancements, and potential future developments in Community-acquired Bacterial Pneumonia areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Community-acquired Bacterial Pneumonia market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Community-acquired Bacterial Pneumonia market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
    Pleuromutilin Antibiotic
    Cephalosporin
    Glycylcycline
    Oxazolidinone
    Ketolide
    Others

Market segment by Application
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

Market segment by players, this report covers
    Nabriva Therapeutics
    Paratek Pharmaceuticals
    Melinta Therapeutics
    Allergan plc
    Bayer AG
    Lupin Pharmaceuticals
    Mylan N.V.
    Sanofi S.A.
    Pfizer Inc.
    Dainippon Sumitomo Pharma
    Takeda Pharmaceutical Company Limited
    Basilea Pharmaceutica International AG

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Community-acquired Bacterial Pneumonia product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Community-acquired Bacterial Pneumonia, with revenue, gross margin and global market share of Community-acquired Bacterial Pneumonia from 2019 to 2024.
Chapter 3, the Community-acquired Bacterial Pneumonia competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Community-acquired Bacterial Pneumonia market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Community-acquired Bacterial Pneumonia.
Chapter 13, to describe Community-acquired Bacterial Pneumonia research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Community-acquired Bacterial Pneumonia
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Community-acquired Bacterial Pneumonia by Type
        1.3.1 Overview: Global Community-acquired Bacterial Pneumonia Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type in 2023
        1.3.3 Pleuromutilin Antibiotic
        1.3.4 Cephalosporin
        1.3.5 Glycylcycline
        1.3.6 Oxazolidinone
        1.3.7 Ketolide
        1.3.8 Others
    1.4 Global Community-acquired Bacterial Pneumonia Market by Application
        1.4.1 Overview: Global Community-acquired Bacterial Pneumonia Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital Pharmacies
        1.4.3 Retail Pharmacies
        1.4.4 Online Pharmacies
    1.5 Global Community-acquired Bacterial Pneumonia Market Size & Forecast
    1.6 Global Community-acquired Bacterial Pneumonia Market Size and Forecast by Region
        1.6.1 Global Community-acquired Bacterial Pneumonia Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Community-acquired Bacterial Pneumonia Market Size by Region, (2019-2030)
        1.6.3 North America Community-acquired Bacterial Pneumonia Market Size and Prospect (2019-2030)
        1.6.4 Europe Community-acquired Bacterial Pneumonia Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size and Prospect (2019-2030)
        1.6.6 South America Community-acquired Bacterial Pneumonia Market Size and Prospect (2019-2030)
        1.6.7 Middle East and Africa Community-acquired Bacterial Pneumonia Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Nabriva Therapeutics
        2.1.1 Nabriva Therapeutics Details
        2.1.2 Nabriva Therapeutics Major Business
        2.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product and Solutions
        2.1.4 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Nabriva Therapeutics Recent Developments and Future Plans
    2.2 Paratek Pharmaceuticals
        2.2.1 Paratek Pharmaceuticals Details
        2.2.2 Paratek Pharmaceuticals Major Business
        2.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Solutions
        2.2.4 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Paratek Pharmaceuticals Recent Developments and Future Plans
    2.3 Melinta Therapeutics
        2.3.1 Melinta Therapeutics Details
        2.3.2 Melinta Therapeutics Major Business
        2.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product and Solutions
        2.3.4 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Melinta Therapeutics Recent Developments and Future Plans
    2.4 Allergan plc
        2.4.1 Allergan plc Details
        2.4.2 Allergan plc Major Business
        2.4.3 Allergan plc Community-acquired Bacterial Pneumonia Product and Solutions
        2.4.4 Allergan plc Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Allergan plc Recent Developments and Future Plans
    2.5 Bayer AG
        2.5.1 Bayer AG Details
        2.5.2 Bayer AG Major Business
        2.5.3 Bayer AG Community-acquired Bacterial Pneumonia Product and Solutions
        2.5.4 Bayer AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Bayer AG Recent Developments and Future Plans
    2.6 Lupin Pharmaceuticals
        2.6.1 Lupin Pharmaceuticals Details
        2.6.2 Lupin Pharmaceuticals Major Business
        2.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Solutions
        2.6.4 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Lupin Pharmaceuticals Recent Developments and Future Plans
    2.7 Mylan N.V.
        2.7.1 Mylan N.V. Details
        2.7.2 Mylan N.V. Major Business
        2.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Product and Solutions
        2.7.4 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Mylan N.V. Recent Developments and Future Plans
    2.8 Sanofi S.A.
        2.8.1 Sanofi S.A. Details
        2.8.2 Sanofi S.A. Major Business
        2.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Product and Solutions
        2.8.4 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Sanofi S.A. Recent Developments and Future Plans
    2.9 Pfizer Inc.
        2.9.1 Pfizer Inc. Details
        2.9.2 Pfizer Inc. Major Business
        2.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Product and Solutions
        2.9.4 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 Pfizer Inc. Recent Developments and Future Plans
    2.10 Dainippon Sumitomo Pharma
        2.10.1 Dainippon Sumitomo Pharma Details
        2.10.2 Dainippon Sumitomo Pharma Major Business
        2.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product and Solutions
        2.10.4 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Dainippon Sumitomo Pharma Recent Developments and Future Plans
    2.11 Takeda Pharmaceutical Company Limited
        2.11.1 Takeda Pharmaceutical Company Limited Details
        2.11.2 Takeda Pharmaceutical Company Limited Major Business
        2.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product and Solutions
        2.11.4 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        2.11.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
    2.12 Basilea Pharmaceutica International AG
        2.12.1 Basilea Pharmaceutica International AG Details
        2.12.2 Basilea Pharmaceutica International AG Major Business
        2.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product and Solutions
        2.12.4 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2024)
        2.12.5 Basilea Pharmaceutica International AG Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Community-acquired Bacterial Pneumonia Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Community-acquired Bacterial Pneumonia by Company Revenue
        3.2.2 Top 3 Community-acquired Bacterial Pneumonia Players Market Share in 2023
        3.2.3 Top 6 Community-acquired Bacterial Pneumonia Players Market Share in 2023
    3.3 Community-acquired Bacterial Pneumonia Market: Overall Company Footprint Analysis
        3.3.1 Community-acquired Bacterial Pneumonia Market: Region Footprint
        3.3.2 Community-acquired Bacterial Pneumonia Market: Company Product Type Footprint
        3.3.3 Community-acquired Bacterial Pneumonia Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Community-acquired Bacterial Pneumonia Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Community-acquired Bacterial Pneumonia Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application (2019-2024)
    5.2 Global Community-acquired Bacterial Pneumonia Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Community-acquired Bacterial Pneumonia Consumption Value by Type (2019-2030)
    6.2 North America Community-acquired Bacterial Pneumonia Consumption Value by Application (2019-2030)
    6.3 North America Community-acquired Bacterial Pneumonia Market Size by Country
        6.3.1 North America Community-acquired Bacterial Pneumonia Consumption Value by Country (2019-2030)
        6.3.2 United States Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        6.3.3 Canada Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        6.3.4 Mexico Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Community-acquired Bacterial Pneumonia Consumption Value by Type (2019-2030)
    7.2 Europe Community-acquired Bacterial Pneumonia Consumption Value by Application (2019-2030)
    7.3 Europe Community-acquired Bacterial Pneumonia Market Size by Country
        7.3.1 Europe Community-acquired Bacterial Pneumonia Consumption Value by Country (2019-2030)
        7.3.2 Germany Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        7.3.3 France Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        7.3.5 Russia Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        7.3.6 Italy Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region
        8.3.1 Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Region (2019-2030)
        8.3.2 China Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        8.3.3 Japan Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        8.3.4 South Korea Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        8.3.5 India Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        8.3.7 Australia Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Community-acquired Bacterial Pneumonia Consumption Value by Type (2019-2030)
    9.2 South America Community-acquired Bacterial Pneumonia Consumption Value by Application (2019-2030)
    9.3 South America Community-acquired Bacterial Pneumonia Market Size by Country
        9.3.1 South America Community-acquired Bacterial Pneumonia Consumption Value by Country (2019-2030)
        9.3.2 Brazil Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        9.3.3 Argentina Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country
        10.3.1 Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Country (2019-2030)
        10.3.2 Turkey Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)
        10.3.4 UAE Community-acquired Bacterial Pneumonia Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Community-acquired Bacterial Pneumonia Market Drivers
    11.2 Community-acquired Bacterial Pneumonia Market Restraints
    11.3 Community-acquired Bacterial Pneumonia Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Community-acquired Bacterial Pneumonia Industry Chain
    12.2 Community-acquired Bacterial Pneumonia Upstream Analysis
    12.3 Community-acquired Bacterial Pneumonia Midstream Analysis
    12.4 Community-acquired Bacterial Pneumonia Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Community-acquired Bacterial Pneumonia Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Community-acquired Bacterial Pneumonia Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Global Community-acquired Bacterial Pneumonia Consumption Value by Region (2019-2024) & (USD Million)
    Table 4. Global Community-acquired Bacterial Pneumonia Consumption Value by Region (2025-2030) & (USD Million)
    Table 5. Nabriva Therapeutics Company Information, Head Office, and Major Competitors
    Table 6. Nabriva Therapeutics Major Business
    Table 7. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product and Solutions
    Table 8. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 9. Nabriva Therapeutics Recent Developments and Future Plans
    Table 10. Paratek Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 11. Paratek Pharmaceuticals Major Business
    Table 12. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Solutions
    Table 13. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 14. Paratek Pharmaceuticals Recent Developments and Future Plans
    Table 15. Melinta Therapeutics Company Information, Head Office, and Major Competitors
    Table 16. Melinta Therapeutics Major Business
    Table 17. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product and Solutions
    Table 18. Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 19. Melinta Therapeutics Recent Developments and Future Plans
    Table 20. Allergan plc Company Information, Head Office, and Major Competitors
    Table 21. Allergan plc Major Business
    Table 22. Allergan plc Community-acquired Bacterial Pneumonia Product and Solutions
    Table 23. Allergan plc Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 24. Allergan plc Recent Developments and Future Plans
    Table 25. Bayer AG Company Information, Head Office, and Major Competitors
    Table 26. Bayer AG Major Business
    Table 27. Bayer AG Community-acquired Bacterial Pneumonia Product and Solutions
    Table 28. Bayer AG Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 29. Bayer AG Recent Developments and Future Plans
    Table 30. Lupin Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 31. Lupin Pharmaceuticals Major Business
    Table 32. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Solutions
    Table 33. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 34. Lupin Pharmaceuticals Recent Developments and Future Plans
    Table 35. Mylan N.V. Company Information, Head Office, and Major Competitors
    Table 36. Mylan N.V. Major Business
    Table 37. Mylan N.V. Community-acquired Bacterial Pneumonia Product and Solutions
    Table 38. Mylan N.V. Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 39. Mylan N.V. Recent Developments and Future Plans
    Table 40. Sanofi S.A. Company Information, Head Office, and Major Competitors
    Table 41. Sanofi S.A. Major Business
    Table 42. Sanofi S.A. Community-acquired Bacterial Pneumonia Product and Solutions
    Table 43. Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 44. Sanofi S.A. Recent Developments and Future Plans
    Table 45. Pfizer Inc. Company Information, Head Office, and Major Competitors
    Table 46. Pfizer Inc. Major Business
    Table 47. Pfizer Inc. Community-acquired Bacterial Pneumonia Product and Solutions
    Table 48. Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 49. Pfizer Inc. Recent Developments and Future Plans
    Table 50. Dainippon Sumitomo Pharma Company Information, Head Office, and Major Competitors
    Table 51. Dainippon Sumitomo Pharma Major Business
    Table 52. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product and Solutions
    Table 53. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 54. Dainippon Sumitomo Pharma Recent Developments and Future Plans
    Table 55. Takeda Pharmaceutical Company Limited Company Information, Head Office, and Major Competitors
    Table 56. Takeda Pharmaceutical Company Limited Major Business
    Table 57. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product and Solutions
    Table 58. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 59. Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
    Table 60. Basilea Pharmaceutica International AG Company Information, Head Office, and Major Competitors
    Table 61. Basilea Pharmaceutica International AG Major Business
    Table 62. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product and Solutions
    Table 63. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 64. Basilea Pharmaceutica International AG Recent Developments and Future Plans
    Table 65. Global Community-acquired Bacterial Pneumonia Revenue (USD Million) by Players (2019-2024)
    Table 66. Global Community-acquired Bacterial Pneumonia Revenue Share by Players (2019-2024)
    Table 67. Breakdown of Community-acquired Bacterial Pneumonia by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 68. Market Position of Players in Community-acquired Bacterial Pneumonia, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
    Table 69. Head Office of Key Community-acquired Bacterial Pneumonia Players
    Table 70. Community-acquired Bacterial Pneumonia Market: Company Product Type Footprint
    Table 71. Community-acquired Bacterial Pneumonia Market: Company Product Application Footprint
    Table 72. Community-acquired Bacterial Pneumonia New Market Entrants and Barriers to Market Entry
    Table 73. Community-acquired Bacterial Pneumonia Mergers, Acquisition, Agreements, and Collaborations
    Table 74. Global Community-acquired Bacterial Pneumonia Consumption Value (USD Million) by Type (2019-2024)
    Table 75. Global Community-acquired Bacterial Pneumonia Consumption Value Share by Type (2019-2024)
    Table 76. Global Community-acquired Bacterial Pneumonia Consumption Value Forecast by Type (2025-2030)
    Table 77. Global Community-acquired Bacterial Pneumonia Consumption Value by Application (2019-2024)
    Table 78. Global Community-acquired Bacterial Pneumonia Consumption Value Forecast by Application (2025-2030)
    Table 79. North America Community-acquired Bacterial Pneumonia Consumption Value by Type (2019-2024) & (USD Million)
    Table 80. North America Community-acquired Bacterial Pneumonia Consumption Value by Type (2025-2030) & (USD Million)
    Table 81. North America Community-acquired Bacterial Pneumonia Consumption Value by Application (2019-2024) & (USD Million)
    Table 82. North America Community-acquired Bacterial Pneumonia Consumption Value by Application (2025-2030) & (USD Million)
    Table 83. North America Community-acquired Bacterial Pneumonia Consumption Value by Country (2019-2024) & (USD Million)
    Table 84. North America Community-acquired Bacterial Pneumonia Consumption Value by Country (2025-2030) & (USD Million)
    Table 85. Europe Community-acquired Bacterial Pneumonia Consumption Value by Type (2019-2024) & (USD Million)
    Table 86. Europe Community-acquired Bacterial Pneumonia Consumption Value by Type (2025-2030) & (USD Million)
    Table 87. Europe Community-acquired Bacterial Pneumonia Consumption Value by Application (2019-2024) & (USD Million)
    Table 88. Europe Community-acquired Bacterial Pneumonia Consumption Value by Application (2025-2030) & (USD Million)
    Table 89. Europe Community-acquired Bacterial Pneumonia Consumption Value by Country (2019-2024) & (USD Million)
    Table 90. Europe Community-acquired Bacterial Pneumonia Consumption Value by Country (2025-2030) & (USD Million)
    Table 91. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Type (2019-2024) & (USD Million)
    Table 92. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Type (2025-2030) & (USD Million)
    Table 93. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Application (2019-2024) & (USD Million)
    Table 94. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Application (2025-2030) & (USD Million)
    Table 95. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Region (2019-2024) & (USD Million)
    Table 96. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value by Region (2025-2030) & (USD Million)
    Table 97. South America Community-acquired Bacterial Pneumonia Consumption Value by Type (2019-2024) & (USD Million)
    Table 98. South America Community-acquired Bacterial Pneumonia Consumption Value by Type (2025-2030) & (USD Million)
    Table 99. South America Community-acquired Bacterial Pneumonia Consumption Value by Application (2019-2024) & (USD Million)
    Table 100. South America Community-acquired Bacterial Pneumonia Consumption Value by Application (2025-2030) & (USD Million)
    Table 101. South America Community-acquired Bacterial Pneumonia Consumption Value by Country (2019-2024) & (USD Million)
    Table 102. South America Community-acquired Bacterial Pneumonia Consumption Value by Country (2025-2030) & (USD Million)
    Table 103. Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Type (2019-2024) & (USD Million)
    Table 104. Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Type (2025-2030) & (USD Million)
    Table 105. Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Application (2019-2024) & (USD Million)
    Table 106. Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Application (2025-2030) & (USD Million)
    Table 107. Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Country (2019-2024) & (USD Million)
    Table 108. Middle East & Africa Community-acquired Bacterial Pneumonia Consumption Value by Country (2025-2030) & (USD Million)
    Table 109. Community-acquired Bacterial Pneumonia Raw Material
    Table 110. Key Suppliers of Community-acquired Bacterial Pneumonia Raw Materials
List of Figures
    Figure 1. Community-acquired Bacterial Pneumonia Picture
    Figure 2. Global Community-acquired Bacterial Pneumonia Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type in 2023
    Figure 4. Pleuromutilin Antibiotic
    Figure 5. Cephalosporin
    Figure 6. Glycylcycline
    Figure 7. Oxazolidinone
    Figure 8. Ketolide
    Figure 9. Others
    Figure 10. Global Community-acquired Bacterial Pneumonia Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 11. Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application in 2023
    Figure 12. Hospital Pharmacies Picture
    Figure 13. Retail Pharmacies Picture
    Figure 14. Online Pharmacies Picture
    Figure 15. Global Community-acquired Bacterial Pneumonia Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 16. Global Community-acquired Bacterial Pneumonia Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 17. Global Market Community-acquired Bacterial Pneumonia Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
    Figure 18. Global Community-acquired Bacterial Pneumonia Consumption Value Market Share by Region (2019-2030)
    Figure 19. Global Community-acquired Bacterial Pneumonia Consumption Value Market Share by Region in 2023
    Figure 20. North America Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 21. Europe Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 22. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 23. South America Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 24. Middle East and Africa Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 25. Global Community-acquired Bacterial Pneumonia Revenue Share by Players in 2023
    Figure 26. Community-acquired Bacterial Pneumonia Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
    Figure 27. Global Top 3 Players Community-acquired Bacterial Pneumonia Market Share in 2023
    Figure 28. Global Top 6 Players Community-acquired Bacterial Pneumonia Market Share in 2023
    Figure 29. Global Community-acquired Bacterial Pneumonia Consumption Value Share by Type (2019-2024)
    Figure 30. Global Community-acquired Bacterial Pneumonia Market Share Forecast by Type (2025-2030)
    Figure 31. Global Community-acquired Bacterial Pneumonia Consumption Value Share by Application (2019-2024)
    Figure 32. Global Community-acquired Bacterial Pneumonia Market Share Forecast by Application (2025-2030)
    Figure 33. North America Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type (2019-2030)
    Figure 34. North America Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application (2019-2030)
    Figure 35. North America Community-acquired Bacterial Pneumonia Consumption Value Market Share by Country (2019-2030)
    Figure 36. United States Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 37. Canada Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 38. Mexico Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 39. Europe Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type (2019-2030)
    Figure 40. Europe Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application (2019-2030)
    Figure 41. Europe Community-acquired Bacterial Pneumonia Consumption Value Market Share by Country (2019-2030)
    Figure 42. Germany Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 43. France Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 44. United Kingdom Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 45. Russia Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 46. Italy Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 47. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type (2019-2030)
    Figure 48. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application (2019-2030)
    Figure 49. Asia-Pacific Community-acquired Bacterial Pneumonia Consumption Value Market Share by Region (2019-2030)
    Figure 50. China Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 51. Japan Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 52. South Korea Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 53. India Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 54. Southeast Asia Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 55. Australia Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 56. South America Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type (2019-2030)
    Figure 57. South America Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application (2019-2030)
    Figure 58. South America Community-acquired Bacterial Pneumonia Consumption Value Market Share by Country (2019-2030)
    Figure 59. Brazil Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 60. Argentina Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 61. Middle East and Africa Community-acquired Bacterial Pneumonia Consumption Value Market Share by Type (2019-2030)
    Figure 62. Middle East and Africa Community-acquired Bacterial Pneumonia Consumption Value Market Share by Application (2019-2030)
    Figure 63. Middle East and Africa Community-acquired Bacterial Pneumonia Consumption Value Market Share by Country (2019-2030)
    Figure 64. Turkey Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 65. Saudi Arabia Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 66. UAE Community-acquired Bacterial Pneumonia Consumption Value (2019-2030) & (USD Million)
    Figure 67. Community-acquired Bacterial Pneumonia Market Drivers
    Figure 68. Community-acquired Bacterial Pneumonia Market Restraints
    Figure 69. Community-acquired Bacterial Pneumonia Market Trends
    Figure 70. Porters Five Forces Analysis
    Figure 71. Manufacturing Cost Structure Analysis of Community-acquired Bacterial Pneumonia in 2023
    Figure 72. Manufacturing Process Analysis of Community-acquired Bacterial Pneumonia
    Figure 73. Community-acquired Bacterial Pneumonia Industrial Chain
    Figure 74. Methodology
    Figure 75. Research Process and Data Source

Companies Mentioned

Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer AG
Lupin Pharmaceuticals
Mylan N.V.
Sanofi S.A.
Pfizer Inc.
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG